Who we are
Angelini Pharma is the pharmaceutical division of Angelini Industries. The Group started almost 100 years ago as a small pharmaceutical laboratory, and over the years has grown into a leading international group in healthcare, present in Pharmaceuticals and Mass-Market.
Angelini Pharma is a leader in healthcare, with particular strength and expertise in the field of Brain Health, including Mental Health and Epilepsy. The company operates across Specialty and Primary Care areas and is also a leading player in the Consumer Health segment, with highly successful OTC brands worldwide.
Angelini Pharma products are marketed in about 70 countries. The company operates directly in 20 countries employing more than 2,800 people, and commercializes its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups.
As part of its internationalisation strategy, Angelini Pharma has also concentrated on development in countries with high growth potential.
Angelini Pharma reported a turnover of €1,2 billion in 2024, about half accounted for by exports.
Over the years, the Research and Development teams at Angelini Pharma discovered and developed several important molecules, among which trazodone and benzydamine. Currently, the programs of research, development, and innovation focus on Brain Health, particularly Mental Health and Epilepsy, and Consumer Health.
Angelini Pharma collaborates with national and global academic institutions and centres of excellence, strongly believing that scientific collaborations play an important role in creating innovation.
Angelini Pharma's "world class" production plants use cutting-edge technologies and have full certification for quality standards and respect for the environment.
In Italy, finished pharmaceutical products are produced in the Ancona plant, while the industrial factory in Aprilia produces pharmaceutical raw materials. These sites make extensive use of renewable energy sources and meet criteria of sustainability. Finally, the Albany (Georgia, USA) plant produces self-heating wraps under the ThermaCare® brand and the Barcelona plant (Spagna) produces food supplements such as Pastillas Juanola.
Angelini Pharma operates in Switzerland with its branch Angelini Pharma Zug S.p.A. (formerly Arvelle Therapeutics International GmbH), which employs approximately 15 people at its headquarters located in Zug, Switzerland. Angelini Pharma acquired Arvelle Therapeutics International GmbH, a biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders in 2021.
In Switzerland, Angelini Pharma markets medicinal products and healthcare solutions with a focus on brain health, notably in epilepsy.
Through multiple partnerships and collaborations with both the private and public sectors the company is determined to improve the lives of patients with epilepsy and to develop new innovations and insights in this area.
To date, Angelini Pharma Switzerland is the Marketing Authorisation Holder of the medicinal product Ontozry® (cenobamate). For further information, please refer to the full Information for Professionals or to the Patient Information Leaflet at www.swissmedicinfo.ch.
To find out more about Angelini Pharma please visit our global site.
